| ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV M Daskou, W Mu, M Sharma, H Vasilopoulos, R Heymans, E Ritou, ... PLoS pathogens 18 (1), e1010160, 2022 | 12 | 2022 |
| Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models A Petcherski, M Sharma, S Satta, M Daskou, H Vasilopoulos, C Hugo, ... bioRxiv, 2022.02. 22.481100, 2022 | 6 | 2022 |
| Endoscopic transsphenoidal surgery for biochemically and clinically non-functioning adenohypophyseal tumours in the elderly: experience from a single UK centre BL Quah, A Edwards-Bailey, K Gnanalingham, O Pathmanaban, ... Endocrine 75 (3), 872-882, 2022 | 5 | 2022 |
| Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic … E Ritou, S Satta, A Petcherski, M Daskou, M Sharma, H Vasilopoulos, ... Metabolism 141, 155395, 2023 | 3 | 2023 |
| Mitoquinone mesylate targets SARS-CoV-2 and associated lung inflammation through host pathways A Petcherski, M Sharma, M Daskou, S Satta, H Vasilopoulos, C Hugo, ... bioRxiv, 2022.02. 22.481100, 2022 | 2 | 2022 |
| Mitoquinone mesylate targets SARS-CoV-2 and associated lung inflammation through host pathways (preprint) A Petcherski, M Sharma, M Daskou, S Satta, H Vasilopoulos, C Hugo, ... | | 2022 |
| In vitro modelling of the therapeutic impact of ApoA-I mimetics on atherogenesis in post-acute COVID-19 syndrome M Sharma, H Vasilopoulos, M Daskou, T Kelesidis Antiviral Therapy, 16-17, 2021 | | 2021 |
| In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV H Vasilopoulos, R Heymans, W Mu, P Hamid, A Kossyvakis, S Sen Roy, ... HIV MEDICINE 20, 98-98, 2019 | | 2019 |
